Cargando…
Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial
BACKGROUND: Pomalidomide in combination with dexamethasone has demonstrated positive results in patients with relapsed or refractory multiple myeloma (RRMM), but no data are available in China. We conducted a multicenter, single-arm trial to examine the efficacy and safety of bioequivalent generic p...
Autores principales: | Fu, Wei-Jun, Wang, Ya-Fei, Zhao, Hong-Guo, Niu, Ting, Fang, Bai-Jun, Liao, Ai-Jun, Bai, Hai, Lu, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250185/ https://www.ncbi.nlm.nih.gov/pubmed/35778685 http://dx.doi.org/10.1186/s12885-022-09802-y |
Ejemplares similares
-
Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018) -
Pomalidomide- and dexamethasone-based regimens in the treatment of
refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022) -
Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
por: Matsue, Kosei, et al.
Publicado: (2015) -
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial
por: Zander, Thilo, et al.
Publicado: (2023) -
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
por: Siegel, David S., et al.
Publicado: (2020)